Sentynl Therapeutics Recognizes Menkes Disease Awareness Month, Committed to the Development of Tests for Early Diagnosis of Patients with Menkes Disease
Sentynl Therapeutics Recognizes Menkes Disease Awareness Month, Supports Development of Tests For Early Diagnosis
- Sentynl Therapeutics Recognizes Menkes Disease Awareness Month, Supports Development of Tests For Early Diagnosis
Today, most patients with Menkes disease are misdiagnosed or diagnosed late after irreversible neurodevelopmental damage has occurred. - Over the last year, Sentynl has been advocating for the inclusion of the ATP7A gene in commercially-available genetic panels.
- We are thrilled to partner with Sentynl Therapeutics in promoting awareness of Menkes disease."
- Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A.